Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 11/20 | 0.46 |
| ▸ | BRD4 | O60885 | 7/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283813 | 0.81 | PTK2 (0.48) | AURKACDK4PTK2JAK2BRD4 | |
| SCHEMBL1654743 | 0.76 | AURKA (0.54) | AURKACDK4PTK2ACVR1JAK2 | |
| SCHEMBL1657524 | 0.75 | AURKA (0.59) | AURKACDK4RIPK2NOD2ACVR1 | |
| SCHEMBL1657463 | 0.75 | JAK2 (0.65) | AURKACDK4PTK2RIPK2NOD2 | |
| SCHEMBL1654519 | 0.74 | AURKA (0.55) | AURKACDK4PTK2RIPK2NOD2 | |
| SCHEMBL1654524 | 0.74 | PTK2 (0.64) | AURKACDK4PTK2RIPK2JAK2 | |
| SCHEMBL1655458 | 0.74 | PTK2 (0.56) | AURKACDK4PTK2JAK2BRD4 | |
| SCHEMBL1657580 | 0.74 | AURKA (0.57) | AURKACDK4PTK2RIPK2NOD2 | |
| SCHEMBL1654998 | 0.73 | JAK2 (0.58) | AURKACDK4PTK2RIPK2NOD2 | |
| SCHEMBL1657468 | 0.73 | AURKA (0.56) | AURKACDK4PTK2RIPK2NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | claimed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | AURKA 755/4885CDK4 186/4885PTK2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.